论文部分内容阅读
慢性乙型肝炎治疗目的在于针对肝脏的炎症,并抑制病毒的活性。对免疫抑制剂治疗慢性活动性乙型肝炎(chronic active hepatitis B,CAH-B)曾有争论。作者对 CAH-B 病例使用短程强的松龙治疗作了初步研究,结果表明血清 HBV-DNA 和乙肝 e 抗原(HBeAg)持续减少,并乙肝表面抗原(HBsAg)滴度下降。作者根据此经验,试图在慢性持续性乙肝(CPH-B)病例,应用激素短程疗法,对改变 HBV 标志物方面有类似作用,目的是降低传染性,使血清转氮酶活性正常化,并改善临床症状。
Chronic hepatitis B treatment aims at inflammation of the liver and inhibits the activity of the virus. There have been controversies about immunosuppressive agents for the treatment of chronic active hepatitis B (CAH-B). The authors conducted a preliminary study of the use of short-course prednisolone in patients with CAH-B and found that serum HBV-DNA and hepatitis B e antigen (HBeAg) levels continued to decrease with a decrease in HBsAg titer. Based on this experience, the authors attempted to apply hormonal brachytherapy in patients with chronic persistent hepatitis B (CPH-B) and have similar effects on the alteration of HBV markers in order to reduce the infectivity, normalize and improve the serum transaminase activity Clinical symptoms.